Welcome to our dedicated page for Capricor Therapeutics SEC filings (Ticker: CAPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Capricor Therapeutics Inc (NASDAQ: CAPR) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Capricor is a Delaware corporation whose common stock trades on The Nasdaq Capital Market under the symbol CAPR, as disclosed in its Form 8-K reports. These filings are a primary source for understanding the company’s financial condition, clinical and regulatory milestones, and material corporate events.
Through this page, readers can review current and historical filings such as Form 8-K reports that announce quarterly financial results, material regulatory updates and other significant developments. For example, Capricor has filed 8-Ks describing the receipt of a Complete Response Letter from the FDA for its Biologics License Application for Deramiocel, subsequent regulatory meetings, and press releases detailing financial results for specific quarters.
Filings also reference key aspects of Capricor’s business, including its focus on Deramiocel, an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy, and its listing of common stock on The Nasdaq Capital Market. These documents may discuss how the company reports results of operations and financial condition, as well as the status of clinical programs and regulatory interactions that are material to the company.
On Stock Titan, each new CAPR filing is captured from EDGAR and paired with AI-powered summaries to help explain the contents in plain language. Users can quickly see the purpose of a filing, identify whether it relates to earnings, regulatory correspondence, financings or other corporate events, and then drill down into the full text if more detail is needed. This structure allows investors and researchers to navigate Capricor’s SEC disclosure record efficiently while retaining access to the underlying official documents.
Highbridge Capital Management, LLC reports beneficial ownership of 1,200,000 shares of Capricor Therapeutics common stock, representing 2.3% of the class. These shares are issuable upon exercise of warrants held by funds it advises.
The 2.3% figure is based on 51,716,975 shares outstanding as of December 5, 2025, after completion of the issuer’s offering and assuming warrant exercise. Highbridge states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Capricor Therapeutics.
Tang Capital Management and related entities have disclosed a significant ownership position in Capricor Therapeutics, Inc. common stock. The group reports beneficial ownership of 3,399,900 shares of Capricor common stock, representing 6.6% of the outstanding shares as of the referenced date. All 3,399,900 shares are reported with shared voting and shared dispositive power, and no shares are reported with sole voting or dispositive power.
Within the group, Tang Capital Partners, LP reports 2,337,350 shares, or 4.5% of the class, and Tang Capital Partners International, LP reports 1,062,550 shares, or 2.1% of the class. Kevin Tang is identified as sharing voting and dispositive power with the Tang Capital entities. The filing is made on Schedule 13G, and the reporting persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Capricor Therapeutics.
Capricor Therapeutics, Inc. reported that its Chief Executive Officer and director, Linda Marban, received new equity awards on January 5, 2026. She was granted stock options to buy 50,000 shares at $24.81 per share that vest in equal monthly installments of 1/48 beginning February 1, 2026, with an early exercise feature that allows purchase before vesting subject to a company repurchase right. She also received stock options for 100,000 shares at $24.81 per share that vest and become exercisable only upon U.S. Food and Drug Administration approval of Deramiocel, contingent on her continued service. In addition, she was granted 7,500 restricted stock units under the 2025 Equity Incentive Plan, vesting 25% annually starting February 1, 2027, also conditioned on continued service.
Capricor Therapeutics reported that its Chief Financial Officer, Anthony Bergmann, received new equity awards on January 5, 2026. He was granted two stock options, each covering 25,000 shares of common stock at an exercise price of $24.81 per share, and 2,500 restricted stock units (RSUs).
One 25,000-share option vests in equal monthly installments of 1/48th beginning on February 1, 2026, and is subject to an early exercise feature, with unvested shares subject to repurchase if his service ends. The second 25,000-share option vests and becomes exercisable on the date of U.S. Food and Drug Administration approval of Deramiocel, conditioned on his continued service.
Each RSU represents one share of common stock under the company’s 2025 Equity Incentive Plan. The 2,500 RSUs were granted as part of the annual equity grant to executive officers and vest 25% annually starting on February 1, 2027, subject to continued service.
Capricor Therapeutics executive Karen Krasney, EVP and General Counsel, reported two new stock option awards. Each award is a stock option to buy 22,500 shares of Capricor common stock at an exercise price of $24.81 per share, with no purchase price for receiving the options themselves. One option grant vests in equal monthly installments of 1/48 of the shares on the first day of each month starting February 1, 2026, until fully vested, and includes an early exercise feature with a company repurchase right if service ends before vesting. The second option grant vests and becomes exercisable only on the date the U.S. Food and Drug Administration approves Deramiocel, subject to Krasney’s continued service with the company through that approval date.
Capricor Therapeutics director Paul Gisbert Auwaerter reported stock option grants for board and committee service. On January 5, 2026, he received three awards of stock options, each with an exercise price of
Capricor Therapeutics director Mike Kelliher reported receiving a stock option grant related to annual board service. On January 5, 2026, he was awarded an option to buy 15,500 shares of common stock at an exercise price of $24.81 per share, all held directly.
The option vests in equal monthly installments, with 1/12 of the grant vesting on the first day of each month starting February 1, 2026, and the final portion vesting on December 31, 2026, after which it is fully vested and exercisable. The option is subject to early exercise, meaning some or all shares can be purchased before they vest, but any such early-exercised shares will be treated as restricted stock and may be repurchased by the company if Kelliher’s service ends before vesting.
Capricor Therapeutics director Philip J. Gotwals received a stock option grant for 15,500 shares on January 5, 2026. The option has a conversion or exercise price of $24.81 per share and was acquired at a price of $0 as compensation.
The award relates to annual board service and vests in monthly installments. One-twelfth of the option vests on the first day of each month starting February 1, 2026, with the final vesting on December 31, 2026, when it becomes fully exercisable. The option is subject to early exercise, meaning all or part of it can be exercised before vesting, but any such early-exercised shares are treated as restricted stock and may be repurchased by the company if Gotwals’ service ends before they vest.
Capricor Therapeutics director Sabar Karimah Es received a new stock option grant related to annual board service. The grant covers 15,500 stock options with an exercise price of $24.81 per share. The options vest in 12 equal monthly installments, with 1/12 of the award vesting on the first day of each month from February 1, 2026 through December 31, 2026, making the option fully vested by year-end 2026.
The option is subject to early exercise, meaning all or part of it can be exercised before vesting. Any shares purchased early are treated as restricted stock and may be repurchased by the company if the director’s service ends before the relevant vesting dates. After this grant, the director beneficially owns 15,500 derivative securities directly.
Capricor Therapeutics director David B. Musket received a new stock option award for 15,500 shares of common stock. The option has an exercise price of $24.81 per share and was granted on January 5, 2026 for his annual board service.
The option vests in equal 1/12 installments on the first day of each month from February 1, 2026 through December 31, 2026, when it becomes fully vested and exercisable. It is also subject to an early exercise feature, allowing Musket to purchase shares before they vest, but any such early‑exercised shares are treated as restricted stock and can be repurchased by the company if his service ends before vesting is complete.